Targeted therapy and molecular genetics

Shannon N. Westin; Anil K. Sood; Robert L. Coleman

doi:10.1016/B978-0-323-77684-4.00024-6

Targeted therapy and molecular genetics

Shannon N. Westin, Anil K. Sood, Robert L. Coleman

Gynecological Oncology & Reproductive Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Expanded understanding of oncogenesis coupled with innovative drug development has enabled a platform for transformative therapy in oncology. The initial results of this expanded paradigm has been higher and more durable objective responses, delay in disease progress and in some cases, prolonged survival. Tremendous progress is also being made in annotating tumors with functionally relevant biomarkers, further illustrating the hope and promise of precision medicine. Herein we provide a detailed account of molecularly targeted agents applied to gynecologic malignancies along with their clinical experience of efficacy and toxicity.

Original language	English (US)
Title of host publication	DiSaia and Creasman Clinical Gynecologic Oncology
Publisher	Elsevier
Pages	464-488
Number of pages	25
ISBN (Electronic)	9780323776844
ISBN (Print)	9780323776868
DOIs	https://doi.org/10.1016/B978-0-323-77684-4.00024-6
State	Published - Jan 1 2023

Keywords

adverse events
antibody drug conjugates
cancer biology
Gynecologic Cancers
immunotherapy
integral and integrated biomarkers
Targeted therapeutics

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-77684-4.00024-6

Cite this

@inbook{b532a317ffe044f78a279e49806bd384,

title = "Targeted therapy and molecular genetics",

abstract = "Expanded understanding of oncogenesis coupled with innovative drug development has enabled a platform for transformative therapy in oncology. The initial results of this expanded paradigm has been higher and more durable objective responses, delay in disease progress and in some cases, prolonged survival. Tremendous progress is also being made in annotating tumors with functionally relevant biomarkers, further illustrating the hope and promise of precision medicine. Herein we provide a detailed account of molecularly targeted agents applied to gynecologic malignancies along with their clinical experience of efficacy and toxicity.",

keywords = "adverse events, antibody drug conjugates, cancer biology, Gynecologic Cancers, immunotherapy, integral and integrated biomarkers, Targeted therapeutics",

author = "Westin, {Shannon N.} and Sood, {Anil K.} and Coleman, {Robert L.}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-77684-4.00024-6",

language = "English (US)",

isbn = "9780323776868",

pages = "464--488",

booktitle = "DiSaia and Creasman Clinical Gynecologic Oncology",

publisher = "Elsevier",

}

TY - CHAP

T1 - Targeted therapy and molecular genetics

AU - Westin, Shannon N.

AU - Sood, Anil K.

AU - Coleman, Robert L.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Expanded understanding of oncogenesis coupled with innovative drug development has enabled a platform for transformative therapy in oncology. The initial results of this expanded paradigm has been higher and more durable objective responses, delay in disease progress and in some cases, prolonged survival. Tremendous progress is also being made in annotating tumors with functionally relevant biomarkers, further illustrating the hope and promise of precision medicine. Herein we provide a detailed account of molecularly targeted agents applied to gynecologic malignancies along with their clinical experience of efficacy and toxicity.

AB - Expanded understanding of oncogenesis coupled with innovative drug development has enabled a platform for transformative therapy in oncology. The initial results of this expanded paradigm has been higher and more durable objective responses, delay in disease progress and in some cases, prolonged survival. Tremendous progress is also being made in annotating tumors with functionally relevant biomarkers, further illustrating the hope and promise of precision medicine. Herein we provide a detailed account of molecularly targeted agents applied to gynecologic malignancies along with their clinical experience of efficacy and toxicity.

KW - adverse events

KW - antibody drug conjugates

KW - cancer biology

KW - Gynecologic Cancers

KW - immunotherapy

KW - integral and integrated biomarkers

KW - Targeted therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85152321476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152321476&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-77684-4.00024-6

DO - 10.1016/B978-0-323-77684-4.00024-6

M3 - Chapter

AN - SCOPUS:85152321476

SN - 9780323776868

SP - 464

EP - 488

BT - DiSaia and Creasman Clinical Gynecologic Oncology

PB - Elsevier

ER -

Targeted therapy and molecular genetics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this